TAS-102
- Generic Name
- TAS-102
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 733030-01-8
- Unique Ingredient Identifier
- -
- Background
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trif...
- Indication
用于治疗曾经接受氟嘧啶，奥沙利铂和伊立替康为基础的化疗，抗VEGF生物治疗和抗EGFR治疗（如果是RAS野生型）无效的转移性结直肠癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- Conditions
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 505
- Registration Number
- NCT05064059
- Locations
- 🇨🇳
Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳Guangxi Medical University Affiliated Tumor Hospital ( Site 1158), Nanning, Guangxi, China
🇨🇳Wuhan Union Hospital Cancer Center ( Site 1162), Wuhan, Hubei, China
AB122 Platform Study
- Conditions
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
Study of CtDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
- Conditions
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 22
- Registration Number
- NCT04920032
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 12
- Registration Number
- NCT04868773
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2022-08-02
- Target Recruit Count
- 27
- Registration Number
- NCT04683965
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
- Conditions
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Gastric Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 116
- Registration Number
- NCT04660760
- Locations
- 🇺🇸
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 33
- Registration Number
- NCT04627961
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage IV Gastroesophageal Junction AdenocarcinomaClinical Stage IVB Gastroesophageal Junction Adenocarcinoma ALocally Advanced Colorectal CarcinomaLocally Advanced Gastroesophageal Junction AdenocarcinomaPostneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT04511039
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 50
- Registration Number
- NCT04294264
- Locations
- 🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood, New Jersey, United States
🇺🇸Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey, United States
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
- Conditions
- Advanced Colorectal CarcinomaMetastatic Colon AdenocarcinomaRecurrent Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Unresectable Colon AdenocarcinomaRecurrent Rectal Adenocarcinoma
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT04109924
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.